Otolaryngology
International clinical evidence for hirudotherapy in hearing loss, sinusitis, and ENT disorders
Ear replantation falls inside the K040187 FDA-cleared device indication; sinusitis, vasomotor rhinitis, and hearing loss are off-label. For tier-based clinical reasoning, see Clinical Knowledge Support.
Off-label use — not FDA-cleared for this indication
Cleared indication: Otolaryngologic applications (sinusitis, hearing loss, vasomotor rhinitis, peritonsillar abscess)
Off-label prescribing is legal in the United States and remains a clinical decision. The discussion below is provided for educational context and does not represent an FDA-cleared indication.
Investigational Application
International Clinical Evidence
The middle ear, paranasal sinuses, and cochlea share end-arterial blood supply, narrow drainage, and fractional-millimeter tolerance for edema. ENT hirudotherapy is documented across 259+ patients in seven investigations (1990-2003): chronic SNHL (n=104), sinusitis (n=60), vasomotor rhinitis (n=55), cochleovestibular disorders (n=40), and inflammatory ear disease. No randomized controlled trial exists for any ENT indication.
Biological Rationale
Microcirculation & Anti-Inflammatory
Histamine-like vasodilator increases periauricular/paranasal capillary flow. Hyaluronidase facilitates lymphatic drainage. Eglins block elastase/cathepsin G; LDTI attenuates mast cell mucosal inflammation; C1s complement inhibitor modulates classical pathway — relevant to sinusitis and neuritis.
Anticoagulant & Lipid
Hirudin prevents fibrinogen clotting. Calin/saratin inhibit platelet adhesion. Destabilase-M lyses fibrin. Lipase and cholesterol esterase reduce circulating lipids. Together these target cochlear ischemia from vertebrobasilar atherosclerosis.
Clinical Evidence
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Seleznev & Shchetinina 1990 | Protocol guidelines + case series | Neuritis, tinnitus, otitis, trigeminal neuralgia (n=NR) | Protocol details in the clinician view | Pain, audiometric noise, electroconductivity | Pain resolved 1-2 sessions; decreased tinnitus; shortened disability In Baskova et al. guidelines; n not reported; Level IV |
| Grigoryev et al. 1998 | Case series | Chronic otitis media with vascular comorbidity (n=NR) | Protocol details in the clinician view | Blood biochemistry, neurological symptoms | Hypercoagulable profile corrected; neurological symptoms resolved Vascular comorbidity mimicking otogenic complications; Level IV |
| Grigoryev & Krymskaya 1998 | Case series | Cochleovestibular disorders, peripheral origin (n=40) | Protocol details in the clinician view | Tinnitus, head heaviness | All 40: reduced tinnitus; subjective lightness in head Vascular etiology; bleeding up to 5h; Level IV |
| Zhuravsky 2000 | Clinical-audiological study (candidate dissertation) | Chronic SNHL: vascular, neurogenic, presbycusic, ototoxic (n=104) | Protocol details in the clinician view | Audiometry, speech comprehension, histology (animal) | Therapeutic effect (vascular/neurogenic); better speech comprehension without threshold change (presbycusis); reduced conductive and sensorineural loss (secondary to chronic middle-ear inflammation); nonspecific stabilizing effect (ototoxic/postinfectious) Largest ENT study; preclinical histologic data; Level IV |
| Moskalenko 2001 | Case series | Acute sinusitis (n=60) | Protocol details in the clinician view | Headache, sinus puncture avoidance, antibiotics | Headache reduced; sinus puncture avoided; antibiotics eliminated Clinically significant procedural sparing; Level IV |
| Krymskaya et al. 2003 | Prospective cohort | Vasomotor rhinitis: idiopathic (20), drug-induced (35) (n=55) | Protocol details in the clinician view | Nasal breathing, medication need; 3-4 month follow-up | Immediate improvement of nasal breathing; medication needed in only 3 hypertensive patients during treatment AE: septal hematoma 1.8%, allergic rhinorrhea 9.1%; Level IV |
| Zhuravsky 2000 | Animal histologic study (preclinical) | Membranous labyrinth (animal model) (n=NR) | Protocol details in the clinician view | Hair cell activity, capillary density, neuroepithelium | Enhanced hair cells; increased stria vascularis capillaries; neuroprotection Structural basis for audiometric improvements; preclinical |
Inflammatory Ear Disease — Historical Report (unverifiable)
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Pain resolved after 1-2 sessions in most cases. Audiometric testing showed decreased tinnitus intensity, skin electroconductivity increased, tissue oxygenation rose, and disability duration shortened.
Chronic Sensorineural Hearing Loss — uncontrolled Russian-language report that is not independently verifiable; no controlled trial exists
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Vascular/Neurogenic
Audiometric threshold improvement. SGS anticoagulant/vasodilatory actions directly target cochlear ischemia from vertebrobasilar compromise. Strongest etiologic response.
Presbycusis
Improved speech comprehension without pure-tone threshold change — central neurovascular processing benefit rather than peripheral hair cell recovery.
Secondary (Middle Ear)
Reduction in both conductive and sensorineural components — combined mechanism via decongestion and microvascular improvement.
Ototoxic/Postinfectious
Nonspecific stabilization of remaining function — neuroprotective rather than regenerative effect.
Cochleovestibular Disorders
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Acute Sinusitis
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Vasomotor Rhinitis
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Outcomes
- Immediate: Improvement or complete restoration of nasal breathing; disappearance of head heaviness; resolution of ear congestion
- Follow-up (3-4 months): During the treatment period, medication was needed in only 3 hypertensive patients
- Pain: No patient reported procedural pain (0/55)
Adverse Events
- Septal hematoma: 1/55 (1.8%) — premature mucocapillary closure; requires prompt drainage
- Allergic rhinorrhea: 5/55 (9.1%) — managed with antihistamines; treatment continued
- 9.1% allergic rate appears elevated relative to reported cutaneous leech-therapy hypersensitivity rates, possibly from nasal mucosal immunoreactivity
Clinical Protocol
Patient Selection & Pre-Procedure
Candidates include patients with otitis, auditory neuritis/tinnitus, chronic SNHL (vascular/neurogenic/presbycusic), acute sinusitis, vasomotor rhinitis, and cochleovestibular disorders with vascular comorbidity. All patients must receive concurrent standard ENT care. Pre-procedure workup: audiometry for hearing indications; sinus probing/lavage to exclude purulent sinusitis (mandatory before endonasal application); blood biochemistry (cholesterol, fibrinogen, prothrombin index); coagulation panel; vertebrobasilar Doppler for vascular etiology; medication review.
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Post-Procedure
Sterile dressing (expect oozing up to 5h periauricular). Audiometric follow-up at course completion. Repeat sinus lavage for obstruction assessment. Blood biochemistry for vascular patients. Nasal septum check at 24-48h post-endonasal. Vasomotor rhinitis: 3-4 month reassessment.
Safety Considerations
- Endonasal bleeding: Kiesselbach plexus = prolonged bleeding. Nasal packing must be available. Contraindicated with anticoagulants without risk-benefit assessment
- Septal hematoma: 1/55 (1.8%); requires prompt drainage to prevent abscess, cartilage necrosis, saddle-nose deformity
- Leech migration (nasal): Aspiration hazard if leech reaches nasopharynx. Syringe containment + continuous monitoring mandatory
- Leech migration (ear canal): Limit to lateral cartilaginous canal; continuous visual monitoring to prevent tympanic membrane contact
- Allergic rate: 9.1% endonasal vs 2-5% cutaneous; manage with antihistamines
- Infection: Aeromonas hydrophila — nasal cavity proximity to sinuses/cavernous sinus. Prophylactic fluoroquinolone or TMP-SMX for endonasal use
- Contraindications: Tympanic membrane perforation; active purulent sinusitis; uncontrolled anticoagulation; known Hirudo allergy; immunocompromise; pediatric patients (not studied)
Drug Interactions
- Anticoagulants/antiplatelets: Additive bleeding. Relative contraindication endonasal; coagulation monitoring periauricular; nasal packing available
- Nasal decongestants: Discontinue before endonasal (therapeutic for rhinitis medicamentosa)
- Antihypertensives: Monitor BP; 25/55 rhinitis patients tolerated concurrent use
- Prophylactic antibiotics: Consider fluoroquinolone/TMP-SMX for endonasal applications (Aeromonas prophylaxis)
Regulatory Status
No regulatory clearance exists for ENT leech applications in the US, EU, or other major jurisdictions. FDA 510(k) K132958 clearance of Hirudo verbana is limited to venous congestion in surgical flaps/replantation. All ENT applications are off-label. In Russia, hirudotherapy is included in ENT protocols at specialist clinics within the national complementary medicine framework.
Evidence Gaps & Research Priorities
No RCT exists for any ENT indication. However, ENT disease offers standardized audiometric/imaging endpoints, quantifiable blood biomarkers, and established comparators (sinus puncture, decongestant withdrawal) that make rigorous investigation feasible. ASH supports development of controlled studies for:
- Chronic SNHL (Priority 1): RCT of HT + standard care vs. standard care in vascular/neurogenic SNHL; audiometric primary endpoint; vertebrobasilar Doppler mechanistic endpoint
- Acute sinusitis (Priority 2): Non-inferiority trial vs. maxillary sinus puncture; CT clearance endpoint; procedural burden and antibiotic use secondary
- Vasomotor rhinitis (Priority 3): Controlled comparison vs. gradual decongestant withdrawal; rhinomanometry and medication-free days endpoints
- Mechanistic studies (Priority 4): SGS effects on mucosal inflammation biomarkers (IL-6, TNF-alpha, mast cell tryptase) and cochlear blood flow (gadolinium MRI or OCT angiography)
Key Takeaways
Largest ENT evidence: 104 SNHL patients (Zhuravsky 2000) with audiometric + preclinical histologic data. A therapeutic effect was reported in chronic SNHL of vascular and neurogenic origin.
Vasomotor rhinitis: immediate improvement of nasal breathing; 3-4 month follow-up; medication needed in only 3 hypertensive patients during treatment. Recommended as therapy of choice (Krymskaya 2003).
Sinusitis: Sinus puncture avoided in 60 patients (Moskalenko 2001) — meaningful procedural sparing.
All Level IV: No RCTs, but ENT offers standardized audiometric/imaging endpoints for rigorous studies. Endonasal risks (migration, hematoma, 9.1% allergy) require specialized training.